Post-earnings recap
Reported
Thu, May 2, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Neurocrine Biosciences is still facing challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 0.91%, reflecting investor concerns about the company's current performance and outlook. Without any guidance provided, uncertainty remains about future growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | -1.12% |
Overall, management expressed concern about current market conditions. They highlighted a commitment to navigating challenges effectively.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve product development.